Ovid Therapeutics Inc. (OVID) Tops Q4 EPS by 4c

Ovid Therapeutics Inc. (NASDAQ: OVID) reported Q4 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $193.5 thousand.

For earnings history and earnings-related data on Ovid Therapeutics Inc. (OVID) click here.

You May Also Be Interested In

• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• JPMorgan Starts Nippon Life India Asset Management Ltd (NAM:IN) at Overweight
• Edgewell stock surges on report of rejected takeover bid